目次

Table of Contents

1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions

2 NAFTA Pharmaceuticals
2.1. Industry Outlook

3 Pharmaceuticals in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis

4 Macroeconomic Indicators
4.1. Country data

5 Pharmaceuticals in Mexico
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis

6 Macroeconomic Indicators
6.1. Country data

7 Pharmaceuticals in The United States
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis

8 Macroeconomic Indicators
8.1. Country data

9 Company Profiles
9.1. Johnson & Johnson
9.2. Apotex, Inc.
9.3. Sanofi SA
9.4. Genomma Lab Internacional SAB de CV
9.5. Merck & Co., Inc.
9.6. Pfizer Inc.
9.7. AstraZeneca PLC

10 Appendix
10.1. Methodology
10.2. About MarketLine

List of Tables
Table 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-27
Table 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-22
Table 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2022-27
Table 4: Canada pharmaceuticals market value: $ billion, 2017-22
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2022
Table 6: Canada pharmaceuticals market value forecast: $ billion, 2022-27
Table 7: Canada size of population (million), 2018-22
Table 8: Canada gdp (constant 2005 prices, $ billion), 2018-22
Table 9: Canada gdp (current prices, $ billion), 2018-22
Table 10: Canada inflation, 2018-22
Table 11: Canada consumer price index (absolute), 2018-22
Table 12: Canada exchange rate, 2018-22
Table 13: Mexico pharmaceuticals market value: $ billion, 2017-22
Table 14: Mexico pharmaceuticals market geography segmentation: $ billion, 2022
Table 15: Mexico pharmaceuticals market value forecast: $ billion, 2022-27
Table 16: Mexico size of population (million), 2018-22
Table 17: Mexico gdp (constant 2005 prices, $ billion), 2018-22
Table 18: Mexico gdp (current prices, $ billion), 2018-22
Table 19: Mexico inflation, 2018-22
Table 20: Mexico consumer price index (absolute), 2018-22
Table 21: Mexico exchange rate, 2018-22
Table 22: United States pharmaceuticals market value: $ billion, 2017-22
Table 23: United States pharmaceuticals market geography segmentation: $ billion, 2022
Table 24: United States pharmaceuticals market value forecast: $ billion, 2022-27
Table 25: United States size of population (million), 2018-22
Table 26: United States gdp (constant 2005 prices, $ billion), 2018-22
Table 27: United States gdp (current prices, $ billion), 2018-22
Table 28: United States inflation, 2018-22
Table 29: United States consumer price index (absolute), 2018-22
Table 30: United States exchange rate, 2018-22
Table 31: Johnson & Johnson: key facts
Table 32: Johnson & Johnson: Annual Financial Ratios
Table 33: Johnson & Johnson: Key Employees
Table 34: Johnson & Johnson: Key Employees Continued
Table 35: Apotex, Inc.: key facts
Table 36: Apotex, Inc.: Key Employees
Table 37: Sanofi SA: key facts
Table 38: Sanofi SA: Annual Financial Ratios
Table 39: Sanofi SA: Key Employees
Table 40: Sanofi SA: Key Employees Continued
Table 41: Genomma Lab Internacional SAB de CV: key facts
Table 42: Genomma Lab Internacional SAB de CV: Annual Financial Ratios
Table 43: Genomma Lab Internacional SAB de CV: Key Employees
Table 44: Merck & Co., Inc.: key facts
Table 45: Merck & Co., Inc.: Annual Financial Ratios
Table 46: Merck & Co., Inc.: Key Employees
Table 47: Merck & Co., Inc.: Key Employees Continued
Table 48: Pfizer Inc.: key facts
Table 49: Pfizer Inc.: Annual Financial Ratios
Table 50: Pfizer Inc.: Key Employees
Table 51: Pfizer Inc.: Key Employees Continued
Table 52: AstraZeneca PLC: key facts
Table 53: AstraZeneca PLC: Annual Financial Ratios
Table 54: AstraZeneca PLC: Key Employees
Table 55: AstraZeneca PLC: Key Employees Continued

List of Figures
Figure 1: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-27
Figure 2: NAFTA countries pharmaceuticals industry, revenue ($bn), 2018-22
Figure 3: NAFTA countries pharmaceuticals industry forecast, revenue ($bn), 2022-27
Figure 4: Canada pharmaceuticals market value: $ billion, 2017-22
Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 6: Canada pharmaceuticals market value forecast: $ billion, 2022-27
Figure 7: Forces driving competition in the pharmaceuticals market in Canada, 2022
Figure 8: Drivers of buyer power in the pharmaceuticals market in Canada, 2022
Figure 9: Drivers of supplier power in the pharmaceuticals market in Canada, 2022
Figure 10: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2022
Figure 11: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2022
Figure 12: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2022
Figure 13: Mexico pharmaceuticals market value: $ billion, 2017-22
Figure 14: Mexico pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 15: Mexico pharmaceuticals market value forecast: $ billion, 2022-27
Figure 16: Forces driving competition in the pharmaceuticals market in Mexico, 2022
Figure 17: Drivers of buyer power in the pharmaceuticals market in Mexico, 2022
Figure 18: Drivers of supplier power in the pharmaceuticals market in Mexico, 2022
Figure 19: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Mexico, 2022
Figure 20: Factors influencing the threat of substitutes in the pharmaceuticals market in Mexico, 2022
Figure 21: Drivers of degree of rivalry in the pharmaceuticals market in Mexico, 2022
Figure 22: United States pharmaceuticals market value: $ billion, 2017-22
Figure 23: United States pharmaceuticals market geography segmentation: % share, by value, 2022
Figure 24: United States pharmaceuticals market value forecast: $ billion, 2022-27
Figure 25: Forces driving competition in the pharmaceuticals market in the United States, 2022
Figure 26: Drivers of buyer power in the pharmaceuticals market in the United States, 2022
Figure 27: Drivers of supplier power in the pharmaceuticals market in the United States, 2022
Figure 28: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2022
Figure 29: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2022
Figure 30: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2022